美国优先审评券对全球卫生研究与开发领域私营部门投资的影响。 - Suppr

Suppr

超能文献

The impact of the US priority review voucher on private-sector investment in global health research and development.

作者信息

Robertson Andrew S, Stefanakis Rianna, Joseph Don, Moree Melinda

机构信息

BIO Ventures for Global Health, San Francisco, California, United States of America.

出版信息

PLoS Negl Trop Dis. 2012;6(8):e1750. doi: 10.1371/journal.pntd.0001750. Epub 2012 Aug 28.

DOI:10.1371/journal.pntd.0001750

PMID:22953004

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3429395/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff4d/3429395/0efdf3fe3428/pntd.0001750.g001.jpg

相似文献

The impact of the US priority review voucher on private-sector investment in global health research and development.

PLoS Negl Trop Dis. 2012;6(8):e1750. doi: 10.1371/journal.pntd.0001750. Epub 2012 Aug 28.

Now we are six.

PLoS Negl Trop Dis. 2012;6(10):e1862. doi: 10.1371/journal.pntd.0001862. Epub 2012 Oct 25.

Research priorities for neglected infectious diseases in Latin America and the Caribbean region.

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e780. doi: 10.1371/journal.pntd.0000780.

Fund global health: Save lives and money.

Science. 2017 Jun 9;356(6342):1018-1019. doi: 10.1126/science.aan4683.

Investment in pneumonia and pneumococcal research.

Lancet Infect Dis. 2014 Nov;14(11):1037-1038. doi: 10.1016/S1473-3099(14)70949-1. Epub 2014 Oct 19.

Global coalition chips away at neglected tropical diseases.

Nature. 2017 Apr 18;544(7650):281-282. doi: 10.1038/544281a.

Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium.

PLoS Negl Trop Dis. 2020 Apr 9;14(4):e0008033. doi: 10.1371/journal.pntd.0008033. eCollection 2020 Apr.

[Neglected tropical diseases - review].

Laeknabladid. 2011 Dec;97(12):693-7. doi: 10.17992/lbl.2011.12.404.

Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom.

BMC Med. 2016 Feb 24;14:32. doi: 10.1186/s12916-016-0564-z.

MDGs and NTDs: reshaping the global health agenda.

PLoS Negl Trop Dis. 2013 Dec 12;7(12):e2529. doi: 10.1371/journal.pntd.0002529. eCollection 2013.

引用本文的文献

Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases.

PLoS Negl Trop Dis. 2023 Nov 13;17(11):e0011760. doi: 10.1371/journal.pntd.0011760. eCollection 2023 Nov.

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review.

PLoS Negl Trop Dis. 2023 Jan 12;17(1):e0011010. doi: 10.1371/journal.pntd.0011010. eCollection 2023 Jan.

Can India lead the way in neglected diseases innovation?

BMJ. 2019 Jan 22;364:k5396. doi: 10.1136/bmj.k5396.

Research for new drugs for elimination of onchocerciasis in Africa.

Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286. doi: 10.1016/j.ijpddr.2016.04.002. Epub 2016 May 19.

Open drug discovery for the Zika virus.

F1000Res. 2016 Feb 9;5:150. doi: 10.12688/f1000research.8013.1. eCollection 2016.

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.

PLoS Negl Trop Dis. 2012;6(10):e1803. doi: 10.1371/journal.pntd.0001803. Epub 2012 Oct 25.

本文引用的文献

Development of and access to products for neglected diseases.

PLoS One. 2010 May 12;5(5):e10610. doi: 10.1371/journal.pone.0010610.

Novartis under fire for accepting new reward for old drug.

Lancet. 2009 Apr 25;373(9673):1414. doi: 10.1016/s0140-6736(09)60804-7.

Neglected disease research and development: how much are we really spending?

PLoS Med. 2009 Feb 3;6(2):e30. doi: 10.1371/journal.pmed.1000030.

Drug development for neglected diseases - the trouble with FDA review vouchers.

N Engl J Med. 2008 Nov 6;359(19):1981-3. doi: 10.1056/NEJMp0806684.

Developing drugs for developing countries.

Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.

Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.

Bull World Health Organ. 2005 Apr;83(4):301-7. Epub 2005 Apr 25.

Drug development for neglected diseases: a deficient market and a public-health policy failure.

Lancet. 2002 Jun 22;359(9324):2188-94. doi: 10.1016/S0140-6736(02)09096-7.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

The impact of the US priority review voucher on private-sector investment in global health research and development.

PLoS Negl Trop Dis. 2012;6(8):e1750. doi: 10.1371/journal.pntd.0001750. Epub 2012 Aug 28.

Now we are six.

PLoS Negl Trop Dis. 2012;6(10):e1862. doi: 10.1371/journal.pntd.0001862. Epub 2012 Oct 25.

Research priorities for neglected infectious diseases in Latin America and the Caribbean region.

PLoS Negl Trop Dis. 2010 Oct 26;4(10):e780. doi: 10.1371/journal.pntd.0000780.

Fund global health: Save lives and money.

Science. 2017 Jun 9;356(6342):1018-1019. doi: 10.1126/science.aan4683.

Investment in pneumonia and pneumococcal research.

Lancet Infect Dis. 2014 Nov;14(11):1037-1038. doi: 10.1016/S1473-3099(14)70949-1. Epub 2014 Oct 19.

Global coalition chips away at neglected tropical diseases.

Nature. 2017 Apr 18;544(7650):281-282. doi: 10.1038/544281a.

Modelling for policy: The five principles of the Neglected Tropical Diseases Modelling Consortium.

PLoS Negl Trop Dis. 2020 Apr 9;14(4):e0008033. doi: 10.1371/journal.pntd.0008033. eCollection 2020 Apr.

[Neglected tropical diseases - review].

Laeknabladid. 2011 Dec;97(12):693-7. doi: 10.17992/lbl.2011.12.404.

Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom.

BMC Med. 2016 Feb 24;14:32. doi: 10.1186/s12916-016-0564-z.

MDGs and NTDs: reshaping the global health agenda.

PLoS Negl Trop Dis. 2013 Dec 12;7(12):e2529. doi: 10.1371/journal.pntd.0002529. eCollection 2013.

引用本文的文献

Public-private partnerships influencing the initiation and duration of clinical trials for neglected tropical diseases.

PLoS Negl Trop Dis. 2023 Nov 13;17(11):e0011760. doi: 10.1371/journal.pntd.0011760. eCollection 2023 Nov.

The United States Food and Drug Administration (FDA) regulatory response to combat neglected tropical diseases (NTDs): A review.

PLoS Negl Trop Dis. 2023 Jan 12;17(1):e0011010. doi: 10.1371/journal.pntd.0011010. eCollection 2023 Jan.

Can India lead the way in neglected diseases innovation?

BMJ. 2019 Jan 22;364:k5396. doi: 10.1136/bmj.k5396.

Research for new drugs for elimination of onchocerciasis in Africa.

Int J Parasitol Drugs Drug Resist. 2016 Dec;6(3):272-286. doi: 10.1016/j.ijpddr.2016.04.002. Epub 2016 May 19.

Open drug discovery for the Zika virus.

F1000Res. 2016 Feb 9;5:150. doi: 10.12688/f1000research.8013.1. eCollection 2016.

Analysis of neglected tropical disease drug and vaccine development pipelines to predict issuance of FDA priority review vouchers over the next decade.

PLoS Negl Trop Dis. 2012;6(10):e1803. doi: 10.1371/journal.pntd.0001803. Epub 2012 Oct 25.

本文引用的文献

Development of and access to products for neglected diseases.

PLoS One. 2010 May 12;5(5):e10610. doi: 10.1371/journal.pone.0010610.

Novartis under fire for accepting new reward for old drug.

Lancet. 2009 Apr 25;373(9673):1414. doi: 10.1016/s0140-6736(09)60804-7.

Neglected disease research and development: how much are we really spending?

PLoS Med. 2009 Feb 3;6(2):e30. doi: 10.1371/journal.pmed.1000030.

Drug development for neglected diseases - the trouble with FDA review vouchers.

N Engl J Med. 2008 Nov 6;359(19):1981-3. doi: 10.1056/NEJMp0806684.

Developing drugs for developing countries.

Health Aff (Millwood). 2006 Mar-Apr;25(2):313-24. doi: 10.1377/hlthaff.25.2.313.

Advance price or purchase commitments to create markets for treatments for diseases of poverty: lessons from three policies.

Bull World Health Organ. 2005 Apr;83(4):301-7. Epub 2005 Apr 25.

Drug development for neglected diseases: a deficient market and a public-health policy failure.

Lancet. 2002 Jun 22;359(9324):2188-94. doi: 10.1016/S0140-6736(02)09096-7.